These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART. Bongiovanni M; Chiesa E; Monforte Ad; Bini T Dermatol Online J; 2003 Dec; 9(5):28. PubMed ID: 14996401 [No Abstract] [Full Text] [Related]
12. [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r]. MMW Fortschr Med; 2003 Dec; 145(50):61. PubMed ID: 14963981 [No Abstract] [Full Text] [Related]
13. Anti-HIV agents. Using only lopinavir/ritonavir (Kaletra). TreatmentUpdate; 2008 Jan; 20(1):1-2. PubMed ID: 18320690 [No Abstract] [Full Text] [Related]
14. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency. Resino S; Bellón JM; Muñoz-Fernández MA; J Antimicrob Chemother; 2006 Mar; 57(3):579-82. PubMed ID: 16446377 [No Abstract] [Full Text] [Related]
15. [After 3 years no resistance development. Protease inhibitor with staying power]. MMW Fortschr Med; 2002 Apr; 144 Suppl 1():56-7. PubMed ID: 12043076 [No Abstract] [Full Text] [Related]
17. Anti-HIV agents. A trial of Kaletra monotherapy. TreatmentUpdate; 2008 Jan; 20(1):2-3. PubMed ID: 18320691 [No Abstract] [Full Text] [Related]
18. [No resistance even after 1 year. New drug combination against HIV]. MMW Fortschr Med; 2001 Apr; 143 Suppl 1():108. PubMed ID: 11373766 [No Abstract] [Full Text] [Related]
19. A king in the CASTLE? Optimum initial HIV protease inhibitor. Torti C; Frank I Lancet; 2008 Aug; 372(9639):604-6. PubMed ID: 18722849 [No Abstract] [Full Text] [Related]